Novavax (NVAX) Current Assets (2010 - 2026)

Novavax's Current Assets history runs 17 years deep, the most recent figure standing at $850.8 million for Q1 2026.

• On a quarterly basis, Current Assets fell 1.98% year-over-year to $850.8 million in Q1 2026; TTM through Mar 2026 was $850.8 million, a 1.98% decrease from a year earlier, with the FY2025 full-year figure at $978.3 million, down 13.35% from the prior year.
• Current Assets eased to $850.8 million in Q1 2026 per NVAX's latest filing, from $978.3 million in the prior quarter.
• Across five years, Current Assets topped out at $2.3 billion in Q1 2022 and bottomed at $727.1 million in Q1 2024.
• The 5-year median for Current Assets is $1.1 billion (2024), against an average of $1.2 billion.
• Across the five-year window, Current Assets slumped 58.63% in 2023 and advanced 19.38% in 2025, its largest moves.
• Year by year, Current Assets stood at $1.7 billion in 2022, then tumbled by 32.85% to $1.1 billion in 2023, then dropped by 1.31% to $1.1 billion in 2024, then dropped by 13.35% to $978.3 million in 2025, then decreased by 13.03% to $850.8 million in 2026.
• Per Business Quant, the three latest NVAX Current Assets figures stand at $850.8 million (Q1 2026), $978.3 million (Q4 2025), and $974.6 million (Q3 2025).